MEDITE Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. MEDITE Cancer Diagnostics, Inc. is headquartered in Orlando, Florida.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone407-996-9630
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.81 million
Profitability
Miscellaneous
Employees69
Next Earnings DateN/A
OptionableNot Optionable
Cytocore (OTCMKTS:MDIT) Frequently Asked Questions
What is Cytocore's stock symbol?
Cytocore trades on the OTCMKTS under the ticker symbol "MDIT."
Has Cytocore been receiving favorable news coverage?
Media stories about MDIT stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cytocore earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the stock's share price in the near term. View News Stories for Cytocore.
Who are some of Cytocore's key competitors?
Some companies that are related to Cytocore include Avinger (AVGR), PlusTherapeuticsInc . (PSTV), Dynatronics (DYNT), Hancock Jaffe Laboratories (HJLI), CELLECT BIOTECH/S (APOP), Valeritas (VLRX), Encision (ECIA), Neurometrix (NURO), Invivo Therapeutics (NVIV), Sintx Technologies (SINT), AdvanSource Biomaterials Corpration (ASNB), Regenicin (RGIN), Nuvectra (NVTR), United American Healthcare (UAHC) and Hypertension Diagnostics (HDII).
What other stocks do shareholders of Cytocore own?
Who are Cytocore's key executives?
Cytocore's management team includes the folowing people:
- Mr. Jeffrey Rencher, Chief Marketing & Bus. Devel. Officer (Age 52)
- Ms. Susan Weisman, Consultant (Age 58)
- Mr. Elmar A. Dave, Chief Exec. Officer
How do I buy shares of Cytocore?
Shares of MDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cytocore's stock price today?
One share of MDIT stock can currently be purchased for approximately $0.03.
How big of a company is Cytocore?
What is Cytocore's official website?
How can I contact Cytocore?
Cytocore's mailing address is 4203 SW 34TH STREET, ORLANDO FL, 32811. The company can be reached via phone at 407-996-9630 or via email at [email protected]
MarketBeat Community Rating for Cytocore (OTCMKTS MDIT)
MarketBeat's community ratings are surveys of what our community members think about Cytocore and other stocks. Vote "Outperform" if you believe MDIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
